PL
CRSP icon

Polianta Ltd’s CRISPR Therapeutics CRSP Stock Holding History

Polianta Ltd’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,200
Closed -$828K – 73
2022
Q1 		$828K Buy
+13,200
New +$829K 0.54% 69

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polianta Ltd's CRSP Position: Q2 2022 in Review

Polianta Ltd sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 13,200 shares — an estimated $828K sold.

Polianta Ltd first reported a position in CRSP in Q1 2022 and held it in 1 quarter. The position peaked at $828K in Q1 2022. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Polianta Ltd reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Polianta Ltd sold 13,200 CRISPR Therapeutics shares in Q2 2022, an estimated $828K.
  • Polianta Ltd first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 1 quarter.
  • Polianta Ltd's CRISPR Therapeutics position peaked at $828K in Q1 2022.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Polianta Ltd's 13F filing for Q2 2022, filed 19 Jul 2022.